Biotech entity
pharma is the sole category represented across all 2 tracked stories. Of the tracked stories, 2 of 2 also mention Gilead Sciences, the most common co-covered peer. Each story carries 2 original sources on average, compared with 4.5 for the broader beat in this window.
Last mentioned: Mar 17, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 2 tracked stories. Of the tracked stories, 2 of 2 also mention Gilead Sciences, the most common co-covered peer. Each story carries 2 original sources on average, compared with 4.5 for the broader beat in this window. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. We currently track 2 Biotech stories that mention ViiV Healthcare, published between March 13, 2026 and March 17, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 63 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ViiV Healthcare. Shared-story counts are live from our verified record — not editorial picks.
New Limits Reported
States begin implementing restrictive eligibility and waitlists for drug assistance programs.
Fiscal Pressure Mounts
Rising costs of long-acting therapies and expiration of pandemic funding strain state budgets.
Waitlist Peak
National ADAP waitlists reached a record high of over 9,000 individuals following the Great Recession.
Ryan White CARE Act
Federal legislation established to provide a safety net for HIV/AIDS care and treatment.
Several states have begun implementing restrictive eligibility requirements and waitlists for AIDS Drug Assistance Programs (ADAPs), citing budgetary shortfalls and rising medication costs. This shift threatens to reverse years of progress in HIV viral suppression and places significant financial pressure on low-income patients and safety-net providers.
The Florida Legislature has approved a stopgap bill to restore essential funding to the state's AIDS Drug Assistance Program (ADAP), averting a potential crisis in medication access. This legislative action ensures that thousands of low-income residents living with HIV/AIDS will continue to receive life-saving antiretroviral treatments without interruption.
ViiV Healthcare is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
